QC Kinetix is a relatively new regenerative clinic brand in the U.S. selling unproven cell therapies. I see several specific red flags including a class action lawsuit. They report having 150+ locations, making it potentially the largest chain of unproven clinics in the U.S. Collectively, these clinics could be seeing tens of thousands of customers. […]
QC Kinetix review: concerns on huge regenerative clinic chain Read More »
I’ve written before about concerns related to longevity research hype from Harvard professor David Sinclair. The media often eats up statements about longevity from Sinclair and a few other scientists in that space. There is also endless coverage of the latest exploits of wealthy health influencer Bryan Johnson. For that reason it was refreshing to
Refreshing WSJ piece on longevity ‘guru’ David Sinclair Read More »
Do our aging cells necessitate that we age overall as people? Flipping it around, if we can stop or reverse enough cellular aging, will our overall aging be positively affected? It’s clear that people age very differently from each other and so do our cells and organs. Interestingly, intramurally in a sense the cells and
Weekly reads: aging cells, scientists relying on ChatGPT, anemone stem cells Read More »
What was the biggest upbeat regenerative medicine story of 2024? I have my own favorites but decided to run a poll. Just putting the poll together, it was evident that this year was unusually full of good and encouraging news. Diabetes and sickle cell regenerative medicine therapies In The Niche polling, so far Vertex Type
Positive regenerative medicine story of the year: diabetes & sickle cell were tops Read More »
The FDA recently warned Frontier Biologics, LLC, a Texas perinatal tissue manufacturer firm. Tallying the many FDA biologics warnings in 2024 It can sometimes feel like there are an uncountable number of unproven stem cell clinics However, the good news is that the FDA has been doing much more on this front in 2024. With
FDA warns Frontier Biologics as part of its more active trend Read More »
Remember former Trump’s FDA Commissioner Scott Gottlieb? Gottlieb’s back in the news in an interesting way related to the upcoming second Trump administration. I just wrote about what to expect from new FDA Commissioner nominee Marty Makary. In that piece, I noted that Scott Gottlieb first came to lead the FDA after a record of
Weekly reads: Scott Gottlieb v. RFK Jr., DNA typewriters, Arnold Caplan Read More »
How might Trump’s nominee to lead the FDA, Martin Makary, change the agency? Should we be worried or hopeful? I’ve been closely following the FDA and its commissioners ever since I started The Niche in 2010. I’ve been particularly interested in how these leaders impacted FDA actions on cell and gene therapies. How might Makaray
What you need to know about Martin Makary and planning for the Trump 2.0 FDA Read More »
What happens if unproven stem cell clinic firms like GIOSTAR start getting okays from the FDA to do clinical trials? On the one hand, it could reflect a positive trend of stem cell clinic firms working with the FDA and toward compliance. Having more robust data. However, I worry about some of these types of
It’s been a long saga for the FDA and the unproven stem cell clinic group called Cell Surgical Network, headquartered in Beverly Hills. A court case involving the two has been unfolding for many years. It has big implications for agency authority and the hundreds of stem cell clinics across the U.S. The case took
After a bit of a hiatus in 2024, our list of regenerative medicine and stem cell meetings returns for 2025. I’m noticing a lot of great stem cell meetings already scheduled for 2025. With the pandemic being less of an ever-present thing, most meetings are now only in-person these days. In a way, the hybrid
2025 regenerative medicine and stem cell meetings list Read More »